Drug Profile
Research programme: pain therapies - ASINEX/Ingenium
Latest Information Update: 17 Jun 2019
Price :
$50
*
At a glance
- Originator ASINEX; Ingenium Pharmaceuticals AG
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 11 Jun 2019 Probiodrug is now called Vivoryon Therapeutics
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in Germany
- 06 Jun 2006 Preclinical trials in Pain in Germany (unspecified route)